TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05974475

Intervention type: RADIATION
Intervention: SBRT
Description: State-of-art SBRT will be delivered in 3-5 fractions; prescription doses and fractionation schedules will be defined according to patient- and tumor-related characteristics (e.g. pulmonary comorbidities, tumor location: peripheral vs central vs ultra-central).

Intervention type: PROCEDURE
Intervention: Surgery
Description: State-of-art surgery will be consist in pulmonary anatomical resection (i.e. segmentectomy or lobectomy) and systematic lymph node dissection.
Study: NCT06183294

Intervention type: OTHER
Intervention: Collecting invasive FFR measurements.
Description: Invasive FFR measurements from the patient's hospital records will be collected.
Study: NCT06057168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elucirem
Description: Intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dotarem
Description: Intravenous administration
Study: NCT05000125

Intervention type: DIAGNOSTIC_TEST
Intervention: Hologic's Genius Digital Diagnostics System
Description: Genius Digital Diagnostics is a digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced volumetric imaging technology to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.
Study: NCT05215223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration
Description: the patients will stand on whole body vibration device with maintaining squatting position while keeping their trunk extended. The first training session will be consisted of three sets of 1 min and will be separated by a 1-min of standing rest. intensity will 1 mm. Then one set will be added every session

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill
Description: Females will be asked to perform moderate intensity aerobic exercise for 45 minutes for 3 times per week for 8 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill
Description: Females will be asked to perform moderate intensity aerobic exercise for 45 minutes for 3 times per week for 8 weeks
Study: NCT04703816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interpersonal Skills Multifaceted Training Program for the physician-patient relationship
Description: The training program consisting of two half-day group workshops with a review of the skills needed to build effective patient relationships and a discussion of difficult consultations based on communication theory like Process-Com® and the Four Habits Model.
Study: NCT05137171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK105 and anlotinib
Description: AK105(penpulimab): 200mg, every 3 weeks, 21 days as a treatment cycle;Anlotinib: 12mg, 2 weeks on/1 week off, 21 days as a treatment cycle;Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, non-adherence to treatment or trial procedures.
Study: NCT05375396

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Streptococcus salivarius M18 lozenges
Description: In this study, a lozenge formulation containing dairy based S. salivarius M18 will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Streptococcus salivarius M18 dairy free lozenges
Description: In this study, a lozenge formulation containing dairy free S. salivarius M18 will be evaluated for its potential of delivering probiotic Streptococcus salivarius M18 to the oral cavity.
Study: NCT06315036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Developmental gymnastics
Description: The DG exercise program ran from September 15, 2021, to May 15, 2022, in a well-equipped gymnasium. Led by trained teachers and gymnastics experts, sessions were held twice weekly (Tuesday and Thursday) for 60 minutes. The program focused on stability, locomotor skills, and manipulation, introducing children to DG fundamentals. It included circuit and station training, obstacle courses, and gradually increased exercise complexity. Sessions comprised a 15-minute warm-up, a 40-minute main session with skill practice and conditioning, and a 5-minute cool-down. The atmosphere was positive and friendly, with kid-friendly music and adapted procedures from previous research.
Study: NCT04903873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU101
Description: EU101 will be administered via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU101
Description: EU101 will be administered via intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU101
Description: EU101 will be administered via intravenous infusion.
Study: NCT05327634

Intervention type: OTHER
Intervention: self-questionnaire
Description: Prospective study on patients aged 75 and over, hospitalised in geriatric short stay or geriatric rehabilitation units
Study: NCT06102122

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Compleat
Description: Patients well established and stable on a standard enteral tube feed with food derived ingredients will act as their own controls and make a product switch
Study: NCT06145165

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nerve block with ropivacaine and intravenous analgesia
Description: When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nerve block with liposomal bupivacaine and intravenous analgesia
Description: When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous analgesia
Description: When the MOAA/S score is 5 after the surgery,the PCIA pump equipped with sufentanil injection will be connected,if the patient's resting NRS ≥ 4 points , they should be given sufentanil 5 ug intravenously at intervals of more than 8 minutes until NRS ≤ 3.
Study: NCT05996055

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: improved version_support device
Description: designed the NTUH version_support device based on the clinical suggestion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: improved version_support device
Description: designed the NTUH version_support device based on the clinical suggestion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: the NTUH version_support device
Description: original designed by NTUH
Study: NCT05756946

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal dressing (coe-pak)
Description: Guided tissue regeneration and periodontal dressing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guided Tissue Regeneration
Description: Regeneration of lost periodontal tissues

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration
Description: Regeneration of lost periodontal tissues
Study: NCT04876365

Intervention type: OTHER
Intervention: Non-Interventional
Description: This is a Non-Interventional Study.
Study: NCT06216678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Dietary Pattern with Cottonseed Oil
Description: Cottonseed Oil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Dietary Pattern with Fatty Acid-Matched Plant Oils
Description: Plant oil blend fatty acid matched

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Dietary Pattern with PUFA:SFA Ratio-Matched Plant Oil
Description: Plant oil with matched PUFA to SFA ratio
Study: NCT05996055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the NTUH version_support device
Description: original designed by NTUH
Study: NCT05671484

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Plane Block
Description: Patients will receive ultrasound-guided quadratus lumborum plane block with 0,3 ml/kg of bupivacaine 0.25% just after general anesthesia induction
Study: NCT05112549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab [Opdivo]
Description: Nivolumab (OPDIVO®) is a marketed pharmaceuticals material authorized in the European Union. This study uses an off-label route of administration of nivolumab. Subjects with leptomeningeal disease in solid tumours with an approved indication for intravenous treatment with the PD1 antibody will receive an intrathecal application of nivolumab. A total of six i.th. applications will be performed every 14 days. The intrathecal administration will be performed via an Ommaya reservoir or another intraventricular catheter.
Study: NCT04713124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: R2C-M
Description: R2C-M comprises 12 modules addressing core practice elements and skills from evidence-based cognitive and behavioural interventions. Modules include: (i) self-monitoring, goal setting and behaviour change skills; (ii) identification of strengths and motivational enhancement; (iii) relapse prevention; (iv) psychoeducation and harm reduction; (v) emotion regulation skills; (vi) anger management skills; (vii) urges and cravings management skills; (viii) sleep hygiene skills; (ix) mindfulness skills; (x) interpersonal skills; (xi) anxiety management skills; (xii) depressed mood management skills. The R2C-M workbooks contain psychoeducation and intervention exercises, to facilitate counsellor-delivered exercises within sessions, and between-session practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-help booklet
Description: A booklet of information and self-help strategies for methamphetamine use problems.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-help booklet
Description: A booklet of information and self-help strategies for methamphetamine use problems.
Study: NCT03607175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone-impregnated CMC foam
Description: same information as included in the arm/group descriptions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Propel Stent
Description: same information as included in the arm/group descriptions
Study: NCT04925193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear export (SINE) compound that specifically blocks exportin 1 (XPO1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Oral Table
Study: NCT06232681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercise
Description: The intervention group will take one month progressive relaxation exercise starting from the hospitalisation to the clinic
Study: NCT05845684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy application
Description: massage, oral and intraoral tactile stimuli and non-nutritive sucking will be performed to stimulate sucking, and massage applications and neurodevelopmental therapy for motor development.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: standard daily applications will be performed on patients
Study: NCT05070598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab +Pyrotinib + Nab-paclitaxel + Tegafur
Description: Camrelizumab was given in the first day of each cycle,Nab-paclitaxel was given in the first day of each cycle, Pyrotinib was given everyday of each cycle, Tegafur given in the day 1-14 of each cycle
Study: NCT05538000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face to face and telephonic interviews
Description: face to face interview : before the first chemotherapy treatment (M0), then at 3 months (M3), 6 months (M6) and 9 months (M9) after the first chemotherapy treatment.~Telephonic interview : every month between two face-to-face interviews, i.e. at 1 month after the first treatment (M1), at 2 months (M2), at 4 months (M4), at 5 months (M5), at 7 months (M7) and at 8 months (M8) after the first chemotherapy treatment.
Study: NCT06402552

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bp-MRI prostate
Description: Biparametric MRI is considered less comprehensive compared to multiparametric MRI (mp-MRI), which includes additional parameters like dynamic contrast-enhanced MRI (DCE-MRI). However, bp-MRI offers a simpler, faster, and often less expensive alternative that still provides critical diagnostic information, particularly in the detection of clinically significant prostate cancer. It's commonly used where less comprehensive assessment is sufficient or in situations where contrast use is contraindicated.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mp-MRI prostate
Description: Multiparametric MRI is highly valued for its ability to improve the detection and characterization of clinically significant prostate cancer, aid in biopsy guidance, and help in treatment planning and monitoring. Its comprehensive approach provides crucial insights that are not as readily available through simpler imaging modalities like biparametric MRI (bp-MRI).
Study: NCT05835375

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EQ-778
Description: 1. capsule daily after breakfast (in case of no URTI episode);~2. capsules after breakfast (in case of URTI episode)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. capsule daily after breakfast (in case of no URTI episode);~2. capsules after breakfast (in case of URTI episode)
Study: NCT05537532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intern Health Study competition-related mobile notification
Description: Participants will receive three types of push notifications: 1. Alert of competition type (steps or sleep) and opponent (Sunday 9pm), 2. Competition score status update (Wednesday 9pm, Saturday 11am), and 3. Competition final results (Monday 12pm).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intern Health Study mobile app
Description: The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intern Health Study mobile app
Description: The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intern Health Study mobile app competition scoreboard and history
Description: Participant can view their current competition scoreboard and competition history at any time via the study app.
Study: NCT04837209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Capsule, taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Intravenous infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radio Therapy
Study: NCT05010369

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: spectroscopic measurement
Description: measurement of the tissue with spectroscopy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: spectroscopic measurement
Description: measurement of the tissue with spectroscopy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: spectroscopic measurement
Description: measurement of the tissue with spectroscopy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: spectroscopic measurement
Description: measurement of the tissue with spectroscopy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: spectroscopic measurement
Description: measurement of the tissue with spectroscopy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FNA biopsy
Description: a fine needle aspiration (FNA) biopsy will be taken

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FNA biopsy
Description: a fine needle aspiration (FNA) biopsy will be taken

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FNA biopsy
Description: a fine needle aspiration (FNA) biopsy will be taken

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FNA biopsy
Description: a fine needle aspiration (FNA) biopsy will be taken

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FNA biopsy
Description: a fine needle aspiration (FNA) biopsy will be taken

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: histopathology and cytology
Description: Histopathology and cytology will be performed on the samples

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: histopathology and cytology
Description: Histopathology and cytology will be performed on the samples

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: histopathology and cytology
Description: Histopathology and cytology will be performed on the samples
Study: NCT04925193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablet or injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablet or injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablet or injection
Study: NCT06202612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302 quick release tablets
Description: SHR0302 quick release tablets 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302 quick release tablets
Description: SHR0302 quick release tablets 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302 sustained-release tablets
Description: SHR0302 sustained-release tablets 10 mg
Study: NCT05010369

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: histopathology and cytology
Description: Histopathology and cytology will be performed on the samples

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: histopathology and cytology
Description: Histopathology and cytology will be performed on the samples
Study: NCT06037096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attend-PE model
Description: A pulmonary embolism follow-up care model consisting of structured elements for follow-up after discharge from hospital.
Study: NCT06202612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302 sustained-release tablets
Description: SHR0302 sustained-release tablets 10 mg
Study: NCT06578416

Intervention type: DIAGNOSTIC_TEST
Intervention: Standardized assessments of speech and language abilities
Description: Standardized and observational assessment of speech and language abilities

Intervention type: DIAGNOSTIC_TEST
Intervention: Standardized assessments of speech and language abilities
Description: Standardized and observational assessment of speech and language abilities
Study: NCT05838027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash Transfer
Description: Participants will receive $125 every 2 weeks for 8 payments via ClinCard, for a total of $1000.
Study: NCT04983875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAC-Enhanced Letter
Description: The BAC-Enhanced Letter intervention includes enhancing the standard mammography results letter with a few additional lines of text informing patients of their personal BAC status.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: BAC-Enhanced Letter
Description: The BAC-Enhanced Letter intervention includes enhancing the standard mammography results letter with a few additional lines of text informing patients of their personal BAC status.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist Control
Description: Patients randomized to this group will receive a standard post-mammography results letter which does not include any information about their personal BAC status. However, participants randomized to this group will be informed of their personal BAC findings at the end of their study participation (approximately 6 months after mammography).
Study: NCT06078202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903
Description: Tablet; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903
Description: Tablet; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903
Description: Tablet; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903
Description: Tablet; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903
Description: Tablet; oral
Study: NCT05365568

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Left Bundle Branch Area Pacing (LBBAP)
Description: Left bundle branch area pacing using conventional stylet driven pacemaker leads for cardiac resynchronization therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biventricular pacing (BiV)
Description: Cardiac resynchronization therapy (CRT) using biventricular pacing (BiV)
Study: NCT04580368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFTR Modulators
Description: Participants with rare mutations will receive active therapy in N-of-1 design with participants serving as their own control
Study: NCT04694755

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On the basis of dextrin and bitter agent, 5% of the drug was used to prepare.Its appearance, weight, color and smell are basically the same as traditional Chinese medicine granule.Tianjiang brand formula granules, in line with GMP standards

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On the basis of dextrin and bitter agent, 5% of the drug was used to prepare.Its appearance, weight, color and smell are basically the same as traditional Chinese medicine granule.Tianjiang brand formula granules, in line with GMP standards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine prescription
Description: Tianjiang brand formula granules, in line with GMP standards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine prescription
Description: Tianjiang brand formula granules, in line with GMP standards